Please assess the completion status of the following clinical trial:

Trial Title: A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically or cytologically proven adenocarcinoma of the colon or rectum.~* Metastatic disease that was not amenable to potentially curative treatment.~* Participants with measurable disease.~* One prior chemotherapeutic regimen (containing oxaliplatin) for metastatic disease.~* Participants who relapsed within 6 months of completion of oxaliplatin-based adjuvant chemotherapy were also eligible.~Exclusion criteria:~* Prior therapy with irinotecan.~* Less than 28 days elapsed from prior radiotherapy, prior surgery, or prior chemotherapy to the time of registration.~* Unresolved toxicity (grade \>1) from prior anticancer therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status \>1.~* Brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis.~* Other prior malignancy.~* Pregnant or breast-feeding women.~* Uncontrolled hypertension.~* Inadequate bone marrow function, liver function, or renal function.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept + FOLFIRI (Type: EXPERIMENTAL): Aflibercept 4 mg/kg intravenous (IV) infusion (1-2 hours) on Day 1 of Cycle 1 and every 2 weeks (q2w) thereafter, in combination with FOLFIRI regimen on Days 1-3 of Cycle 1 and q2w thereafter until disease progression (DP), unacceptable toxicity or participant's refusal. FOLFIRI regimen: IV infusions of levofolinate 200 mg/m\^2 (2 hours) and irinotecan 180 mg/m\^2 (90 minutes) simultaneously, followed by 5-FU 400 mg/m\^2 IV bolus injection followed by continuous IV infusion of 5-FU (46 hours) at 2400 mg/m\^2.

Based on this trial design, predict the completion outcome and termination type (if applicable).